Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Recurrence 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancy 1MDS 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × eprenetapopt × Clear all
NCT02098343 2025-03-17

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Aprea Therapeutics

Phase 1/2 Completed
247 enrolled 15 charts
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03268382 2025-03-17

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Aprea Therapeutics

Phase 2 Completed
36 enrolled 13 charts
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡